Comparison of Insulin Glargine Versus NPH Insulin in People with Type 2 Diabetes Mellitus Under Outpatient-Clinic Conditions for 18 Months Using a Basal-Bolus Regimen with a Rapid-Acting Insulin Analogue as Mealtime Insulin

2007 ◽  
Vol 115 (06) ◽  
pp. 349-353 ◽  
Author(s):  
T. Siegmund ◽  
S. Weber ◽  
H. Blankenfeld ◽  
A. Oeffner ◽  
P.-M. Schumm-Draeger
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Glargine ◽  
Insulin Analogue ◽  
Nph Insulin ◽  
Acting Insulin ◽  
Mealtime Insulin ◽  
Basal Bolus

scholarly journals Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety

2021 ◽  
pp. 246-255
Author(s):  
E. V. Biryukova ◽  
M. V. Shinkin ◽  
O. M. Mikheeva
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Glargine ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Acting Insulin ◽  
Modern Analogue ◽  
Long Acting

In time, prescription of insulin therapy (IT) becomes inevitable for many patients with type 2 diabetes mellitus (DM) to achieve and maintain the target hypoglycemic range.According to the current guidelines, the addition of basal insulin to glucose-lowering therapy in patients with insufficient control of type 2 diabetes, gradual titration of its dose in accordance with a fasting blood glucose level is an effective and safe method for initiating IT. The properties of modern long-acting insulin analogues are considered. Glargine 300 U/ml is a modern analogue of long-acting insulin that is intended to be used once a day. The glargine molecule forms the basis of the drug. Increasing the concentration of glargine per volume unit and formation of a smaller subcutaneous depot led to a change in the pharmacokinetic properties of the drug. Glargine 300 IU/ml provides a more stable, long-term, predictable action with low glycemic variability as compared with glargine 100 IU/ml, which reduces the risk of hypoglycemia. The sugar-reducing efficacy and safety of insulin glargine 300 U/ml as evidenced by the findings of the international clinical phase III EDITION studies are discussed. Insulin glargine 300 U/ml showed a similar decrease in HbA1c levels compared to insulin glargine 100 U/ml with an improved safety profile (lower risk of developing episodes of confirmed or severe hypoglycemia at all times of the day, including the nighttime) and a less pronounced effect on the body weight of patients with type 2 diabetes. The efficacy and safety of the use of glargine 300 U/ml has been confirmed in type 2 diabetes patients with chronic kidney disease and the elderly. In the BRIGHT study, glargine 300 U/ml showed comparable glycemic control when it is being compared. 

scholarly journals The efficacy of insulin glargine under real clinical practice conditions: results of the LAURUS-2 observational program

2011 ◽  
Vol 57 (6) ◽  
pp. 15-20
Author(s):  
S A Skudaev ◽  
N I Verbovaia
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Practice ◽  
Insulin Glargine ◽  
Carbohydrate Metabolism ◽  
Dose Titration ◽  
Efficacy And Safety ◽  
Nph Insulin

The objective of the Program is to estimate the efficacy and safety of insulin glargine (Lantus) used in routine clinical practice for the treatment of patients presenting with type 2 diabetes mellitus who failed to reach adequate compensation of the disease by therapy with two hyperglycemic agents in combination with NPH insulin and have a glycated hemoglobin level in excess of 7.0%. The data obtained by examining 2395 patients (755 men and 1640 women) were available for analysis. 2157 patients (685 men and 1472 women) were transferred to insulin glargine therapy whereas the remaining 238 ones (70 men and 168 women) continued to use NPH insulin. The patients of the former group were offered two algorithms for dose titration of glargine (Lantus). Significant improvement of the parameters of carbohydrate metabolism was achieved within 12 weeks after the onset of therapy without the risk of hypoglycemia. It is concluded that the results of the Program demonstrate a higher efficacy and safety of insulin glargine compared with NPH insulin for the treatment of the patients with type 2 diabetes mellitus. The use of a simple dose titration algorithm and glycemic self-control makes it possible to quickly, safely, and efficiently achieve optimal parameters of carbohydrate metabolism in the majority of the patients treated with insulin glargine at a low incidence of episodes of all types of hypoglycemia.

Sign in / Sign up

Export Citation Format

Share Document